Trading on Gulf Pharmaceutical Industries (JULPHAR) shares resumed on February 13, 2026, following the release of preliminary results for the fiscal year ended December 31, 2025.
Net profit for the year reached AED 175.3 million, a significant increase from AED 35.0 million in 2024, supported by a one-off capital gain of AED 118.7 million.
Revenues from continuing operations grew 6.8% to AED 1,059.7 million, while EBITDA from continuing operations rose 15% to AED 101.9 million.
Earnings per share improved to AED 0.15, compared to a loss per share of AED 0.01 in the previous fiscal year.